Monitor the October 26 special meeting outcome and any stockholder dissent; the merger is the primary catalyst. Preclinical data is early-stage and does not change near-term deal risk.
Price Chart
Executive Summary
Pulmatrix filed a 425 communication highlighting preclinical data for Eos SENOLYTIX's lead candidate PTC-2105, showing attenuation of terminal lean-mass decline and mitigation of semaglutide-associated lean-mass loss in aged mice. The filing also confirms the merger timeline: the special meeting of Pulmatrix stockholders is set for October 26, 2026, with closing expected shortly after, subject to stockholder approval and customary conditions. No changes to deal terms or opposition were disclosed.
Key Financial Metrics
Key Facts
- PTC-2105 monotherapy reversed terminal lean-mass trajectory from decline to net gain in aged mice (+0.005 vs saline -0.002 g/wk).
- Semaglutide alone showed steepest terminal lean-mass decline (-0.055 g/wk) with shorter survival (p=0.038); PTC-2105+semaglutide arms reduced this loss.
- Pulmatrix special meeting for stockholder vote on merger with Eos is scheduled for October 26, 2026.
- Merger is anticipated to close shortly after the special meeting, subject to stockholder approval and customary conditions.
- Combined company common stock expected to trade on Nasdaq under ticker 'MTXL'.
- Registration statement on Form S-4 declared effective by SEC on September 25, 2026; proxy statement/prospectus filed and supplemented on October 7, 2026.
Financial Impact
No financial figures disclosed; preclinical data only; merger-associated financings expected to support pipeline advancement but amounts not specified.
Risk Factors
- Failure to obtain stockholder approval for the merger.
- Preclinical results may not translate to clinical outcomes.
- Ability to secure necessary financings for combined company operations.
- Regulatory and Nasdaq listing risks post-merger.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-046691 |
| Document: 0001493152-26-046691-index-headers.html | 0001493152-26-046691 |
| Document: 0001493152-26-046691-index.html | 0001493152-26-046691 |
| Document: 0001493152-26-046691.txt | 0001493152-26-046691 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 6d ago | EFFECT | $1.48 | awaiting T+5 | awaiting T+5 | $1.50 (−1.35%) |
Oct 22, 2026 7d ago | 425 | $1.42 | awaiting T+5 | awaiting T+5 | $1.50 (+5.63%) |
Oct 13, 2026 16d ago | 425 | $1.38 $1.43 | ▲ +3.62% | ▲ +4.77% | $1.50 (+8.70%) |
Oct 7, 2026 21d ago | DEFA14A | $1.53 $1.41 | ▼ −7.67% | ▼ −7.39% | $1.50 (−1.77%) |
Oct 2, 2026 26d ago | S-3/A | $1.48 $1.43 | ▲ +3.38% | ▲ +3.80% | $1.50 (−1.35%) |
Sep 28, 2026 4w ago | EFFECT | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.50 (+5.66%) |
Sep 25, 2026 4w ago | DEFM14A | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.50 (+5.66%) |
Sep 23, 2026 5w ago | S-4/A | $1.67 $1.54 | ▼ −7.78% | ▼ −7.37% | $1.50 (−10.18%) |
Sep 22, 2026 5w ago | 425 | $1.69 $1.52 | ▼ −9.79% | ▼ −9.12% | $1.50 (−10.98%) |
Sep 17, 2026 5w ago | S-4/A | $1.44 $1.61 | ▲ +11.81% | ▲ +10.54% | $1.50 (+4.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers